vs

Side-by-side financial comparison of Business First Bancshares, Inc. (BFST) and RIGEL PHARMACEUTICALS INC (RIGL). Click either name above to swap in a different company.

Business First Bancshares, Inc. is the larger business by last-quarter revenue ($83.1M vs $69.8M, roughly 1.2× RIGEL PHARMACEUTICALS INC). On growth, RIGEL PHARMACEUTICALS INC posted the faster year-over-year revenue change (21.2% vs 7.1%). Over the past eight quarters, RIGEL PHARMACEUTICALS INC's revenue compounded faster (53.7% CAGR vs 16.8%).

First Citizens Bancshares, Inc. is a bank holding company based in Raleigh, North Carolina and one of the largest banks in the United States. Its primary subsidiary is First Citizens Bank, which operates over 500 branches in 23 states. A second subsidiary is Silicon Valley Bank, which operates 39 offices in 15 states.

Rigel Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing targeted small molecule therapies for autoimmune, inflammatory, and hematologic diseases. Its approved flagship product treats adult immune thrombocytopenia, with primary operations and core markets in the United States, addressing unmet medical needs for underserved patient groups.

BFST vs RIGL — Head-to-Head

Bigger by revenue
BFST
BFST
1.2× larger
BFST
$83.1M
$69.8M
RIGL
Growing faster (revenue YoY)
RIGL
RIGL
+14.1% gap
RIGL
21.2%
7.1%
BFST
Faster 2-yr revenue CAGR
RIGL
RIGL
Annualised
RIGL
53.7%
16.8%
BFST

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BFST
BFST
RIGL
RIGL
Revenue
$83.1M
$69.8M
Net Profit
$268.1M
Gross Margin
91.5%
Operating Margin
33.2%
33.2%
Net Margin
384.0%
Revenue YoY
7.1%
21.2%
Net Profit YoY
1769.2%
EPS (diluted)
$0.71
$14.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BFST
BFST
RIGL
RIGL
Q4 25
$83.1M
$69.8M
Q3 25
$80.9M
$69.5M
Q2 25
$81.5M
$101.7M
Q1 25
$79.2M
$53.3M
Q4 24
$77.6M
$57.6M
Q3 24
$66.9M
$55.3M
Q2 24
$66.2M
$36.8M
Q1 24
$60.9M
$29.5M
Net Profit
BFST
BFST
RIGL
RIGL
Q4 25
$268.1M
Q3 25
$22.9M
$27.9M
Q2 25
$22.1M
$59.6M
Q1 25
$20.5M
$11.4M
Q4 24
$14.3M
Q3 24
$17.8M
$12.4M
Q2 24
$17.2M
$-1.0M
Q1 24
$13.6M
$-8.2M
Gross Margin
BFST
BFST
RIGL
RIGL
Q4 25
91.5%
Q3 25
93.2%
Q2 25
95.6%
Q1 25
91.7%
Q4 24
89.9%
Q3 24
85.5%
Q2 24
92.4%
Q1 24
93.1%
Operating Margin
BFST
BFST
RIGL
RIGL
Q4 25
33.2%
33.2%
Q3 25
35.7%
40.9%
Q2 25
34.4%
60.1%
Q1 25
32.6%
23.9%
Q4 24
27.5%
28.9%
Q3 24
34.0%
25.4%
Q2 24
32.9%
1.2%
Q1 24
28.2%
-23.6%
Net Margin
BFST
BFST
RIGL
RIGL
Q4 25
384.0%
Q3 25
28.2%
40.2%
Q2 25
27.1%
58.6%
Q1 25
25.9%
21.5%
Q4 24
24.9%
Q3 24
26.7%
22.5%
Q2 24
26.0%
-2.8%
Q1 24
22.3%
-27.9%
EPS (diluted)
BFST
BFST
RIGL
RIGL
Q4 25
$0.71
$14.11
Q3 25
$0.73
$1.46
Q2 25
$0.70
$3.28
Q1 25
$0.65
$0.63
Q4 24
$0.51
$0.82
Q3 24
$0.65
$0.70
Q2 24
$0.62
$-0.06
Q1 24
$0.48
$-0.47

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BFST
BFST
RIGL
RIGL
Cash + ST InvestmentsLiquidity on hand
$411.2M
$155.0M
Total DebtLower is stronger
$52.5M
Stockholders' EquityBook value
$896.9M
$391.5M
Total Assets
$8.2B
$513.6M
Debt / EquityLower = less leverage
0.13×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BFST
BFST
RIGL
RIGL
Q4 25
$411.2M
$155.0M
Q3 25
$399.1M
$137.1M
Q2 25
$495.8M
$108.4M
Q1 25
$312.9M
$77.1M
Q4 24
$319.1M
$77.3M
Q3 24
$213.2M
$61.1M
Q2 24
$208.1M
$49.1M
Q1 24
$185.9M
$49.5M
Total Debt
BFST
BFST
RIGL
RIGL
Q4 25
$52.5M
Q3 25
$60.0M
Q2 25
$60.0M
Q1 25
$60.0M
Q4 24
$60.0M
Q3 24
$60.0M
Q2 24
$60.0M
Q1 24
$60.0M
Stockholders' Equity
BFST
BFST
RIGL
RIGL
Q4 25
$896.9M
$391.5M
Q3 25
$878.4M
$117.6M
Q2 25
$848.4M
$81.9M
Q1 25
$826.3M
$18.6M
Q4 24
$799.5M
$3.3M
Q3 24
$699.5M
$-14.6M
Q2 24
$664.5M
$-29.9M
Q1 24
$649.0M
$-31.7M
Total Assets
BFST
BFST
RIGL
RIGL
Q4 25
$8.2B
$513.6M
Q3 25
$8.0B
$242.5M
Q2 25
$7.9B
$206.7M
Q1 25
$7.8B
$176.0M
Q4 24
$7.9B
$164.0M
Q3 24
$6.9B
$139.4M
Q2 24
$6.7B
$128.4M
Q1 24
$6.7B
$126.5M
Debt / Equity
BFST
BFST
RIGL
RIGL
Q4 25
0.13×
Q3 25
0.51×
Q2 25
0.73×
Q1 25
3.23×
Q4 24
18.25×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BFST
BFST
RIGL
RIGL
Operating Cash FlowLast quarter
$92.1M
$22.0M
Free Cash FlowOCF − Capex
$92.0M
FCF MarginFCF / Revenue
110.7%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
0.08×
TTM Free Cash FlowTrailing 4 quarters
$165.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BFST
BFST
RIGL
RIGL
Q4 25
$92.1M
$22.0M
Q3 25
$32.4M
$24.0M
Q2 25
$14.0M
$30.5M
Q1 25
$28.7M
$-893.0K
Q4 24
$61.4M
$14.5M
Q3 24
$21.4M
$21.7M
Q2 24
$15.1M
$302.0K
Q1 24
$7.6M
$-5.0M
Free Cash Flow
BFST
BFST
RIGL
RIGL
Q4 25
$92.0M
Q3 25
$32.1M
Q2 25
$13.8M
Q1 25
$27.7M
Q4 24
$59.8M
Q3 24
$21.0M
Q2 24
$14.0M
Q1 24
$7.2M
FCF Margin
BFST
BFST
RIGL
RIGL
Q4 25
110.7%
Q3 25
39.6%
Q2 25
16.9%
Q1 25
34.9%
Q4 24
77.1%
Q3 24
31.4%
Q2 24
21.2%
Q1 24
11.8%
Capex Intensity
BFST
BFST
RIGL
RIGL
Q4 25
0.1%
Q3 25
0.4%
Q2 25
0.3%
Q1 25
1.3%
Q4 24
2.0%
Q3 24
0.6%
Q2 24
1.6%
Q1 24
0.6%
Cash Conversion
BFST
BFST
RIGL
RIGL
Q4 25
0.08×
Q3 25
1.42×
0.86×
Q2 25
0.63×
0.51×
Q1 25
1.40×
-0.08×
Q4 24
1.01×
Q3 24
1.20×
1.75×
Q2 24
0.88×
Q1 24
0.56×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons